PROGNOSTIC SIGNIFICANCE OF ESTROGEN AND PROGESTERONE RECEPTOR EXPRESSION IN PATIENTS WITH STAGE I–II ENDOMETRIAL CANCER

Abstract

Summary. Aim: to assess the expression levels of estrogen (ER) and progesterone (PR) receptors in patients with different histological and molecular subtypes of endometrial cancer and to determine their association with survival outcomes. Object and methods: a prospective study was conducted involving 455 patients with stage I–II endometrial cancer who received treatment at the Prykarpattia Clinical Oncology Center of the Ivano- Frankivsk Regional Council from 2021 to 2024. The majority of patients were women over 60 years old — 291 (64.0%). Endometrioid adenocarcinoma was the predominant histological subtype and was diagnosed in 76.9% cases. Tumors with low and moderate differentiation (G1–2) were found in 57.4% patients. Results: imunohistochemical analysis revealed ER+/PR+ status in 55.8% patients, while ER–/PR– tumors were present in ISSN 3083-7154, 1562-1774 • ОНКОЛОГІЯ • Т. 27 • № 3 • 2025 2 0 1 Прогностичне значення експресії рецепторів естрогенів і прогестерону при раку ендометрію I–II стадії Одержано: 06.10.2025 Прийнято до друку: 12.11.2025 Опубліковано: 27.11.2025 29.7% cases. Endometrioid endometrial carcinoma was more common among hormone receptor-positive tumors ER+/PR+ (72.8%), whereas non-endometrioid carcinomas more frequently exhibited hormone receptor-negative status ER–/PR– (61.9%). Patients with ER+/PR+ tumors demonstrated the highest three-year overall survival (OS) rate of 93.7%, in the ER–/PR– group OS reached 71.9%. Conclusions. ER and PR expression serves as an important prognostic marker in patients with stage I–II endometrial cancer. A positive ER/PR status is associated with favorable clinicopathological characteristics and improved survival outcomes. Patients with ER+/PR+ tumors demonstrated better OS compared to those with ER–/PR– status.